Cadrenal Registers 2.94M Shares for Resale from $3M PIPE, Unlocking Up to $6M in Warrant Proceeds
CVKD is trading near its 52-week low of $2.34 (5.1% above the low) on elevated volume (3.6× avg).
Summary
Cadrenal filed an S-3 to register 2.94 million shares for resale by investors from its July 1 PIPE, potentially bringing in up to $6 million if warrants are exercised, but creating significant dilution risk with shares equal to 49% of the current float.
Key Events · Financing and Capital Events · CVKD
-
Resale Registration Filed
Cadrenal registered 2,942,400 shares for resale by selling stockholders from the July 1 PIPE, including 2.88M shares underlying investor warrants and 62,400 shares underlying placement agent warrants.
-
Potential Proceeds from Warrant Exercises
If all warrants are exercised for cash, the company could receive approximately $5.8 million from investor warrants and $244,000 from placement agent warrants, providing critical funding for operations.
-
Significant Dilution Overhang
The registered shares represent 49% of the current 3.1 million shares outstanding. Full exercise would increase shares outstanding to 6.0 million, substantially diluting existing holders.
-
Liquidated Damages Clause
The registration rights agreement requires effectiveness within 45–75 days; failure triggers liquidated damages of 1.0% of the $3M investment per 30-day period, capped at 6.0%.
Analysis · CVKD · Life Sciences
This S-3 registers the resale of 2.94 million shares underlying warrants from the July 1 PIPE, enabling the selling stockholders to sell into the market. While the company gets no proceeds from those sales, it could receive up to $6 million if all warrants are exercised for cash — critical runway for a company with a going concern warning and cash only into October 2026. The filing also reveals a liquidated damages clause (up to 6% of the $3M investment) if registration deadlines are missed, and lock-up restrictions that limit near-term capital raises. The registration itself creates an overhang: the 2.94 million shares represent 49% of the current outstanding, and any sales could pressure the stock, which already trades at $2.46, below the $3.00 warrant exercise price.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1944 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVKD was trading at $2.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $2.34 to $14.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.